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Abstract
Aims: This study aimed to evaluate final adult height (AH) 
after recombinant human growth hormone (GH) treatment 
of girls with Turner syndrome (TS) and to elucidate the pre-
dicting factors for their growth response. Methods: We en-
rolled 73 patients with TS who underwent GH treatment and 
reached AH and 14 patients who did not undergo treat-
ment. To assess the effectiveness of GH therapy, we evalu-
ated final AH, height gain over the predicted AH, and height 
gain over the projected AH. In addition, to analyze the fac-
tors affecting final AH, we studied correlations between final 
AH (or height SDS, height gain) and treatment variables. Re-
sults: GH therapy was started at a mean age of 8.87 ± 3.73 
years, and the treatment duration was 6.47 ± 3.02 years. The 
patients in the treated group reached a final AH of 152.03 ± 
4.66 cm (final AH SDS for the general population: –1.93 ± 
1.03) with a gain over projected AH at the start of treatment 
of 12.21 ± 4.33 cm. The untreated control subjects had a final 
AH of 143.57 ± 4.06 cm with a gain over projected AH at the 
first visit of 3.89 ± 3.80 cm. Final AH and AH SDS were posi-
tively correlated to height SDS at the start of treatment. Thir-
ty-five patients out of the 73 GH-treated patients (47.9%) 
attained to a normal range of height for Korean girls. The 
patients having attained to a normal height range after GH 
treatment had shown a higher height SDS at the start of GH 
treatment, a higher mid-parental height SDS, and a younger 
age at initiation of estrogen. Conclusions: Our findings 
demonstrate that GH treatment at an early age is effective 
in improving the final height SDS and height SDS gain in TS 
patients. Therefore, GH administration at an early age is im-
portant for final height gain. © 2019 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Turner syndrome (TS) is a chromosomal disorder 
caused by complete or partial monosomy of the X chro-
mosome in a phenotypic female, which is associated with 
a short stature and primary ovarian failure. Short stature 
is the most common clinical feature of TS [1]. Prenatal 
growth failure followed by impaired childhood growth 
and the absence of a pubertal growth spurt in patients 
with TS result in a final height that is approximately 
20 cm shorter than that of the normal female population. 
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The etiology of growth failure in TS is not well under-
stood. It is supposed that haploinsufficiency of the short 
stature homeobox-containing (SHOX) gene contributes 
more to short stature than a disturbance of the growth 
hormone (GH)-insulin-like growth factor (IGF) axis [2].
Although recombinant human GH has been prescribed 
to improve adult height (AH) in TS patients for decades, the 
response of patients to GH treatment is variable and de-
pends on the treatment protocol (e.g., dosage, age at initia-
tion of treatment, and age at puberty onset) [3–10]. The 
guidelines of the Turner Syndrome Study Group recom-
mend that GH should be administered at the US Food and 
Drug Administration (FDA)-approved dose of 1.125 IU/
kg/week (0.375 mg/kg/week); this dose can be adapted ac-
cording to the growth response and IGF-1 levels [1]. It is also 
recommended that GH treatment should be considered as 
soon as growth failure is evident, possibly around 4–6 years 
of age. Estrogen therapy to induce pubertal development 
should be started between 11 and 12 years of age [11].
In this retrospective study, we assessed the effect of GH 
replacement therapy on final AH by comparing the final 
AHs of TS patients undergoing GH therapy with those of 
TS patients without GH treatment, as well as height SDS 
(standard deviation score) gain after treatment. In addi-
tion, we analyzed contributing factors determining the 
effect of GH treatment on final AH.
Subjects and Methods
This retrospective study included 92 patients with TS who were 
followed up at the Department of Pediatrics of Severance Chil-
dren’s Hospital, South Korea, and reached final AH. The study 
participants were recruited from the database of the hospital that 
includes subjects diagnosed with TS based on peripheral blood 
karyotyping between January 1986 and December 1997. We en-
rolled 74 patients with TS who underwent GH treatment and 
reached AH and 18 patients who did not undergo treatment.
Recombinant GH was administered subcutaneously, every eve-
ning, at the fixed dose of 1 IU/kg/week (0.33 mg/kg/week) until 
final AH was reached. The untreated control group included pa-
tients visiting the hospital too late to undertake GH treatment. 
Conjugated estrogens were initiated at a mean age of 14.76 ± 1.96 
years in the GH-treated group, and at 17.63 ± 2.96 years in the un-
treated group. A small daily dose of estradiol valerate (0.25 mg) 
was given for the first 1 or 2 years, which was gradually increased 
to 1 mg, followed by cyclic administration of 1 mg of estrogen (es-
tradiol valerate) for 25 days, combined for the last 10 days with 
progesterone (medroxyprogesterone 10 mg/day).
We evaluated the subjects’ height, weight, BMI, and bone age 
(BA) before and during the GH treatment. The patients visited the 
outpatient clinic for follow-up every 3 months. At each visit, height 
(to the nearest 0.1 cm) was measured using a Harpenden Stadiom-
eter, and weight was recorded to the nearest 0.1 kg. Growth param-
eters, including height, weight, and BMI, are expressed as SDS and 
were calculated using the growth standard for Korean children and 
adolescents [12] and the reference growth chart for Korean girls 
with TS [13]. Mid-parental height (MPH) was defined as the mean 
of the parental height minus 6.5 cm. BA was assessed according to 
the Greulich-Pyle method by the same observer [14]. Predicted 
AH was calculated according to the Bayley-Pinneau method [15]. 
Projected AH was calculated according to the projected final 
height method [16] based on the reference growth chart for Ko-
rean girls with TS [13]. Final AH was defined as the height ob-
served for at least 1 year without any further increase > 1 cm after 
the discontinuation of GH treatment.
To assess the effectiveness of GH therapy, we evaluated final 
AH, height SDS gain for the general population and TS (Δ between 
the final AH SDS and initial height SDS), height gain over the pre-
dicted AH (Δ between final AH and predicted AH at baseline), and 
height gain over the projected AH (Δ between final AH and pro-
jected AH at baseline). In addition, to analyze the factors affecting 
final AH in the GH treatment group, we studied correlations be-
tween final AH (or height SDS for the general population and TS, 
height gain over predicted AH) and baseline and treatment vari-
ables. BA, complete blood cell counts, routine chemistry, and thy-
roid function, as well as hemoglobin A1c, IGF-1, and IGF-binding 
protein 3 levels were monitored every 6 months.
Statistical Analysis
Continuous variables are expressed as means ± SD for normal-
ly distributed data. Multiple regression analysis was used to evalu-
ate the relationship between the height outcomes and clinical pa-
rameters. All data were analyzed using SPSS version 15.0 (SPSS 
Inc., Chicago, IL, USA). p values < 0.05 were used as the cutoff for 
statistical significance.
Results
Clinical Characteristics of the Subjects at Baseline and 
at the Endpoint
We compared the clinical characteristics of the 73 TS 
patients who underwent human GH treatment to those 
of the 14 patients who did not undertake GH treatment 
at baseline and at the endpoint (Table 1). At the first visit, 
the mean age of the untreated and the treated group was 
17.32 ± 2.8 and 8.87 ± 3.73 years, respectively. Although 
the height SDS for the general population at the first visit 
were lower in the untreated control group than in the 
treated group, MPH, height SDS for age-specific TS, pre-
dicted AH, and projected AH were not different.
After GH treatment, the final AH was 143.57 ± 4.06 cm 
in the untreated control group and 152.03 ± 4.66 cm in the 
treated group. The mean duration of GH treatment was 
6.47 ± 3.02 years. According to the growth standard for 
Korean children and adolescents, the final AH SDS was 
–3.87 and –1.93 in the untreated and the treated group, 
respectively. According to the reference growth chart for 
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Korean girls with TS, it was 0.51 and 1.60, respectively. 
Final AH and height SDS had significantly increased in 
the subjects with GH treatment. The height SDS gain for 
age-specific TS was 0.41 ± 0.91 and 1.27 ± 0.84 in the un-
treated and the treated group, respectively. Final AH was 
7.6 cm above the Bayley-Pinneau prediction at baseline, 
and 12.21 cm above the projected AH at baseline.
Figure 1 shows the baseline height and final AH for all 
subjects. Thirty-five (47.9%) of the 73 recipients of GH 
(Fig.  1a) had heights above the 3rd percentile on the 
growth chart for normal Korean girls, whereas no one in 
the untreated group attained heights above the 3rd per-
centile for normal Korean girls (Fig. 1b).
Predictors of Final AH in Patients with TS Undergoing 
GH Treatment
We analyzed the factors affecting the final growth out-
come in the GH treatment group. AH in centimeters as 
well as height SDS for the general population and age-
specific TS were correlated with only height SDS at the 
start of GH treatment. AH in centimeters or SDS for the 
general population and age-specific TS did not show any 
correlation with chronological age at the start of GH 
treatment, MPH SDS, duration of therapy, and age at ini-
tiation of estrogen. No correlation was found between the 
gain over projected AH and chronological age at the start 
of GH treatment, height SDS at the start, MPH SDS, and 
duration of therapy (Table 2).
Comparison of the Clinical Characteristics between 
the Group Having Attained to a Normal Height Range 
and the Group Who Did Not after GH Treatment
We compared the clinical characteristics between the 
group having attained to a normal height range (higher 
than the 3rd percentile on the growth chart for normal 
Korean girls) and the group who did not (below the 3rd 
percentile on the growth chart for normal Korean girls) 
after GH treatment. Thirty-five patients out of the 73 GH-
treated patients (47.9%) attained to a normal height range 
on the growth chart for normal Korean girls. The patients 
having attained to a normal height range after GH treat-
ment (n = 35) showed a higher height SDS at the start of 
GH treatment, a higher MPH SDS, and a younger age at 
initiation of estrogen (Table 3).
Table 1. Baseline characteristics and final adult height of the patients with Turner syndrome with and without 
GH treatment
Treated group
(n = 73)
Untreated controls
(n = 14)
At first visit
Chronological age, years 8.87±3.73 17.32±2.8
Bone age, years 8.06±3.48 14.00±1.46
Height, cm 114.41±21.3 137.8±5.89
Mid-parental height, cm 158.50±3.41 158.17±5.80
Height SDS (general population) –2.71±1.03 –4.48±1.04
Height SDS (age-specific Turner syndrome) 0.33±1.03 0.10±1.04
Predicted adult height, cm 144.39±7.81 141.30±5.34
Projected adult height, cm 139.82±0.63 139.67±0.67
45,X karyotype, n (%) 26/73 (35) 0/14 (0)
At attainment of adult height
Chronological age, years 15.40±1.46 20.31±2.23
Bone age, years 14.78±0.55 15.78±0.43
Height, cm 152.03±4.66 143.57±4.06
Height SDS (general population) –1.93±1.03 –3.87±0.98
Height SDS (age-specific Turner syndrome) 1.60±0.59 0.51±0.52
Treatment duration, years 6.47±3.02 –
Height SDS gain (general population) 0.79±1.05 0.60±0.59
Height SDS gain (age-specific Turner syndrome) 1.27±0.84 0.41±0.91
Height gain from predicted adult height, cm 7.6±6.44 2.26±3.85
Height gain from projected adult height, cm 12.21±4.33 3.89±3.80
GH, growth hormone; SDS, standard deviation score.
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Discussion
In this study we analyzed final AH in patients with TS 
who underwent GH treatment or not. The mean final AH 
in the GH-treated group was 152.03 cm, which is 12.21 ± 
4.33 cm taller than their projected AH based on Korean 
TS-specific data, and 7.6 ± 6.44 cm taller than their pre-
dicted AH based on the Bayley-Pinneau prediction meth-
od. The final AH in our study is comparable to previous 
reports of AHs of girls with GH-treated TS from France 
(147.8 cm) [4], the Netherlands (151.3 cm) [4], Germany 
(151.9 cm) [4], the UK (150.7 cm) [4], Norway (151.7 cm) 
Table 2. Correlation between growth outcome and clinical characteristics in the GH-treated group
AH, cm Height SDS
(general population)
Height SDS
(Turner syndrome)
Gain over 
projected AH, cm
R2 p value R2 p value R2 p value R2 p value
Chronological age at start, years 0.202 0.364 0.198 0.375 0.206 0.354 –0.4 0.078
Height SDS at start 0.504 0.036 0.481 0.046 0.511 0.036 0.204 0.349
MPH SDS 0.192 0.084 0.201 0.073 0.192 0.085 –0.121 0.344
Treatment duration, years 0.029 0.890 0.028 0.897 0.030 0.887 –0.429 0.061
GH, growth hormone; SDS, standard deviation score; AH, adult height; MPH, mid-parental height.
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Fig. 1. Height of Turner syndrome patients plotted on the growth 
curve for normal girls (dashed lines) and for Turner syndrome 
girls (solid lines). Height before treatment (filled circles) and after 
treatment (triangles) in growth hormone-treated patients (a), and 
height at the first visit (filled circles) and at adult age (triangles) in 
untreated patients (b).
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[4], Japan (144.3 cm) [17], and the USA (150.4 cm) [18], 
as well as population-based cohort studies from France 
(149.9 cm) [19] and Italy (151 cm) [20]. Although the pre-
vious studies were undertaken in different years (1980–
1990s) and with slightly different treatment protocols, 
they demonstrated a similar final AH attained and that 
there was a beneficial effect of GH on final AH.
Meanwhile, it is noteworthy that the height gain over 
the projected AH at the start observed in our study (12.21 
cm) exceeded those observed in other countries (range: 
1.8–9.0 cm), as did the height gain over the predicted AH 
at the start (7.6 cm in this study; 3.3 cm in other countries) 
[4, 19, 20]. The greater height gain over the projected or 
the predicted AH seen in our study compared to other 
countries might be due to the younger age of the subjects 
at the start of therapy (8.87 years in this study; 10.9–14.6 
years in other countries), the longer duration of treat-
ment (6.47 years in this study; 4.5–7.6 years in other 
countries), and the larger dose of GH (1.0 IU/kg/week in 
this study; 0.7–1.0 IU/kg/week in other countries) [4, 17–
20].
In our study, we selected as the untreated control 
group those patients having visited the hospital too late 
to undertake GH treatment, and they were matched for 
the same MPH and projected AH at the first visit, though 
not in a randomized fashion. The mean final AH in the 
untreated group was 143.57 cm, which was 3.89 ± 3.80 cm 
taller than their projected AH based on Korean TS-spe-
cific data, and 2.26 ± 3.85 cm taller than their predicted 
AH based on the Bayley-Pinneau prediction method. The 
mean final AH of Korean girls with untreated TS was sim-
ilar to those reported in previous studies from other 
countries, i.e., the UK (142.9 cm) [16], the USA (144.2 cm) 
[18], Italy (144.3 cm) [20], Germany (146.8 cm) [21], 12 
European countries (144.3 cm) [9], Japan (136.8 cm) [22], 
and China (141.46 cm) [23]. In our study, the height gains 
over the projected or predicted AH at the start in the GH-
treated group were greater than those in the untreated 
controls, suggesting that GH treatment of patients with 
TS augments the final AH.
Previous studies have demonstrated that the growth 
response after GH treatment for TS was related to height 
and height SDS at the start of treatment [4, 20], MPH or 
target height [4, 19, 20, 24], BA delay [4, 19, 24], GH dos-
age [4, 19], duration of treatment [19, 24], age at the start 
of treatment [19, 24], and age at pubertal onset [19, 24]. 
In our study, only height SDS at the start of treatment was 
correlated with AH in centimeters, and AH SDS for the 
general population and TS. When the clinical character-
istics were compared between the group having attained 
to a normal range of height in the general population and 
the group who did not after GH treatment, those patients 
with a higher height SDS at the start of GH treatment, a 
higher MPH SDS, and a younger age at initiation of estro-
Table 3. Comparison of the clinical characteristics between the group having attained to a normal height range and the group who did 
not after GH treatment
Group having attained to a
normal height range (n = 35)
Group not having attained to a
normal height range (n = 38)
p value
Chronological age at start, years 8.80±3.30 8.86±4.13 0.874
Height at start, cm 118.39±15.23 110.75±25.32 0.127
Height SDS at start (general population) –2.3±1.0 –3.09±0.92 0.001
Height SDS at start (Turner syndrome) 0.77±0.97 –0.07±0.92 0.000
MPH SDS –0.28±1.0 –1.0±0.9 0.002
BA – CA –0.97±1.01 –0.67±1.60 0.328
Treatment duration, years 6.28±2.66 6.65±3.35 0.616
Age at initiation of estrogen, years 14.7±1.17 15.48±1.43 0.017
45,X karyotype, % 56.7 51.2 0.416
Adult height, cm 155.72±2.77 148.6±3.24 0.000
Adult height SDS (general population) –1.11±0.58 –2.68±0.75 0.000
Adult height SDS (Turner syndrome) 2.07±0.35 1.17±0.42 0.000
Height SDS gain (general population) 1.19±0.83 0.41±1.1 0.001
Height SDS gain (Turner syndrome) 1.30±0.83 1.23±0.86 0.741
Height gain over predicted adult height, cm 7.18±6.58 8.0±0.64 0.631
Height gain over projected adult height, cm 15.62±2.5 9.06±3.09 0.000
GH, growth hormone; SDS, standard deviation score; MPH, mid-parental height; BA, bone age; CA, chronological age.
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gen tended to attain to a normal range of height. In con-
trast, chronological age at the start of treatment, BA delay, 
and duration of therapy did not influence attainment to 
a normal range of height after treatment.
These discrepancies between factors affecting the de-
termination of final AH may derive from differences in 
study population size, ethnicity, and treatment protocol. 
Our data suggest that final AH in TS is correlated with 
height SDS at the start of treatment, and attainment to a 
normal range of height in the general population is main-
ly determined by factors that reflect the genetically deter-
mined growth channel, such as MPH and height SDS at 
the start of treatment, which is similar to the results of a 
previous study [4].
In our study, initiation of estrogen at an earlier age 
seems to have been more effective for attainment to a nor-
mal height range in the general population. However, we 
could not determine the exact effect of early initiation of 
estrogen because of the very late initiation of estrogen 
treatment in our retrospective study. A previous study on 
the impact of age at estrogen replacement on final height 
showed that patients in whom estrogen treatment had 
been initiated at the age of 15 years had gained 3.3 cm 
more AH than those in whom estrogen treatment had 
been initiated at the age of 12 years [25], whereas other 
cohort studies found no effect of age at estrogen replace-
ment [26, 27]. A more recent randomized study on 
whether to begin estrogen treatment early (at 12.0–12.9 
years of age) or late (at 14.0–14.9 years of age) showed 
that very-low-dose estrogen replacement permits age-ap-
propriate feminization without interfering with the effect 
of GH on TS [28]. Another study, a double-blind, place-
bo-controlled, randomized trial on optimizing estrogen 
replacement, demonstrated that combining childhood 
ultralow-dose estrogen with GH may improve growth 
and other potential benefits associated with early initia-
tion of estrogen replacement [29].
In conclusion, our study shows that GH treatment ini-
tiated at an early age increases the final AH and height 
gain in patients with TS. The data also show that nearly 
half of the patients attain to an AH in the normal range 
of height for the normal population after GH treatment. 
In our study, attainment to a normal height after treat-
ment depended on height SDS at the start of treatment, 
the genetically determined growth potential (MPH SDS), 
and earlier replacement of estrogen.
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